Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 5 EP applications Birgit Otzen Petersen has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 18, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP13720714

HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS

IPC classification:
C07K 16/28
Applicant:
Novo Nordisk A/S
Applicant:
Amgen Inc
Agent:
Birgit Otzen Petersen, Novo Nordisk A/S
Status:
EXAMINATION IN PROGRESS
EP14708903

GROWTH HORMONE COMPOUNDS

IPC classification:
C07K 19/00, C12N 5/10, C12P 21/02
Applicant:
Novo Nordisk Health Care AG
Agent:
Birgit Otzen Petersen, Novo Nordisk A/S
Status:
EXAMINATION IN PROGRESS
EP14715022

GROWTH HORMONE COMPOUND FORMULATION

IPC classification:
A61K 38/27, A61K 47/10, A61K 47/18, A61K 47/26, A61K 47/48
Applicant:
Novo Nordisk Health Care AG
Agent:
Birgit Otzen Petersen, Novo Nordisk A/S
Status:
EXAMINATION REQUESTED
EP11731397

GROWTH HORMONE CONJUGATES

IPC classification:
A61K 47/48, A61P 5/06
Applicant:
Novo Nordisk Health Care AG
Agent:
Birgit Otzen Petersen, Novo Nordisk A/S
Status:
APPLICATION WITHDRAWN
EP14818938

METHOD FOR THIOETHER CONJUGATION OF PROTEINS

IPC classification:
A61K 47/48, C07K 14/00
Applicant:
Novo Nordisk Health Care AG
Agent:
Birgit Otzen Petersen, Novo Nordisk A/S
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature